Literature DB >> 11159991

Antibody responses to infections with strains of Plasmodium falciparum expressing diverse forms of merozoite surface protein 2.

S Weisman1, L Wang, H Billman-Jacobe, D H Nhan, T L Richie, R L Coppel.   

Abstract

Individuals living in areas where Plasmodium falciparum is endemic experience numerous episodes of infection. These episodes may or may not be symptomatic, with the outcome depending on a combination of parasite and host factors, several of which are poorly understood. One factor is believed to be the particular alleles of several parasite proteins to which the host is capable of mounting protective immune responses. We report a study examining antibody responses to MSP2 in 15 semi-immune teenagers and adults living in the Khanh-Hoa area of southern-central Vietnam, where P. falciparum is highly endemic; subjects were serially infected with multiple strains of P. falciparum. The MSP2 alleles infecting these subjects were determined by nucleotide sequencing. A total of 62 MSP2 genes belonging to both dimorphic families were identified, of which 33 contained distinct alleles, with 61% of the alleles being detected once. Clear changes in the repertoire occurred between infections. Most infections contained a mixture of parasites expressing MSP2 alleles from both dimorphic families. Two examples of reinfection with a strain expressing a previously encountered allele were detected. Significant changes in antibody levels to various regions of MSP2 were detected over the course of the experiment. There was no clear relation between the infecting form of MSP2 and the ensuing antibody response. This study highlights the complexity of host-parasite relationship for this important human pathogen.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159991      PMCID: PMC97975          DOI: 10.1128/IAI.69.2.959-967.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Structural and antigenic polymorphism of the 35- to 48-kilodalton merozoite surface antigen (MSA-2) of the malaria parasite Plasmodium falciparum.

Authors:  B Fenton; J T Clark; C M Khan; J V Robinson; D Walliker; R Ridley; J G Scaife; J S McBride
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

2.  IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria.

Authors:  R R Taylor; S J Allen; B M Greenwood; E M Riley
Journal:  Am J Trop Med Hyg       Date:  1998-04       Impact factor: 2.345

3.  Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria.

Authors:  F al-Yaman; B Genton; R Anders; J Taraika; M Ginny; S Mellor; M P Alpers
Journal:  Parasite Immunol       Date:  1995-09       Impact factor: 2.280

4.  Plasmodium falciparum genetic diversity can be characterised using the polymorphic merozoite surface antigen 2 (MSA-2) gene as a single locus marker.

Authors:  N Prescott; A W Stowers; Q Cheng; A Bobogare; C M Rzepczyk; A Saul
Journal:  Mol Biochem Parasitol       Date:  1994-02       Impact factor: 1.759

5.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

6.  Structural diversity in the 45-kilodalton merozoite surface antigen of Plasmodium falciparum.

Authors:  J A Smythe; M G Peterson; R L Coppel; A J Saul; D J Kemp; R F Anders
Journal:  Mol Biochem Parasitol       Date:  1990-03       Impact factor: 1.759

7.  Temporal variation of the merozoite surface protein-2 gene of Plasmodium falciparum.

Authors:  D Eisen; H Billman-Jacobe; V F Marshall; D Fryauff; R L Coppel
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

8.  Allelic variants of the Plasmodium falciparum merozoite surface antigen 2 (MSA-2) in a geographically restricted area of Irian Jaya.

Authors:  V M Marshall; R L Anthony; M J Bangs; R F Anders; R L Coppel
Journal:  Mol Biochem Parasitol       Date:  1994-01       Impact factor: 1.759

Review 9.  Molecular variation in Plasmodium falciparum: polymorphic antigens of asexual erythrocytic stages.

Authors:  R F Anders; D J McColl; R L Coppel
Journal:  Acta Trop       Date:  1993-05       Impact factor: 3.112

10.  Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.

Authors:  L Rénia; I T Ling; M Marussig; F Miltgen; A A Holder; D Mazier
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

View more
  18 in total

1.  Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies.

Authors:  Janine Stubbs; Sope Olugbile; Balam Saidou; Jacques Simpore; Giampietro Corradin; Antonio Lanzavecchia
Journal:  Infect Immun       Date:  2010-12-28       Impact factor: 3.441

Review 2.  Antigenic diversity and immune evasion by malaria parasites.

Authors:  Marcelo U Ferreira; Mônica da Silva Nunes; Gerhard Wunderlich
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

3.  Plasmodium falciparum merozoite surface protein 6 displays multiple targets for naturally occurring antibodies that mediate monocyte-dependent parasite killing.

Authors:  Subhash Singh; Soe Soe; Christian Roussilhon; Giampietro Corradin; Pierre Druilhe
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

4.  Strain-specific humoral response to a polymorphic malaria vaccine.

Authors:  Christian Flück; Tom Smith; Hans-Peter Beck; Andrea Irion; Inoni Betuela; Michael P Alpers; Robin Anders; Allan Saul; Blaise Genton; Ingrid Felger
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

5.  Allelic family-specific humoral responses to merozoite surface protein 2 (MSP2) in Gabonese residents with Plasmodium falciparum infections.

Authors:  M-T Ekala; H Jouin; F Lekoulou; O Mercereau-Puijalon; F Ntoumi
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

6.  Allele-specific antibodies to Plasmodium falciparum merozoite surface protein-2 and protection against clinical malaria.

Authors:  F H A Osier; L M Murungi; G Fegan; J Tuju; K K Tetteh; P C Bull; D J Conway; K Marsh
Journal:  Parasite Immunol       Date:  2010-03       Impact factor: 2.280

7.  Antigenic characterization of an intrinsically unstructured protein, Plasmodium falciparum merozoite surface protein 2.

Authors:  Christopher G Adda; Christopher A MacRaild; Linda Reiling; Kaye Wycherley; Michelle J Boyle; Vivian Kienzle; Paul Masendycz; Michael Foley; James G Beeson; Raymond S Norton; Robin F Anders
Journal:  Infect Immun       Date:  2012-09-10       Impact factor: 3.441

8.  Plasmodium falciparum populations from northeastern Myanmar display high levels of genetic diversity at multiple antigenic loci.

Authors:  Lili Yuan; Hui Zhao; Lanou Wu; Xiaomei Li; Daniel Parker; Shuhui Xu; Yousheng Zhao; Guohua Feng; Ying Wang; Guiyun Yan; Qi Fan; Zhaoqing Yang; Liwang Cui
Journal:  Acta Trop       Date:  2012-09-20       Impact factor: 3.112

9.  Effect of Plasmodium yoelii exposure on vaccination with the 19-kilodalton carboxyl terminus of merozoite surface protein 1 and vice versa and implications for the application of a human malaria vaccine.

Authors:  Jiraprapa Wipasa; Huji Xu; Xueqin Liu; Chakrit Hirunpetcharat; Anthony Stowers; Michael F Good
Journal:  Infect Immun       Date:  2008-11-17       Impact factor: 3.441

10.  Genetic diversity and antigenic polymorphism in Plasmodium falciparum: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2.

Authors:  Simon Franks; Luke Baton; Kevin Tetteh; Eric Tongren; David Dewin; Bartholomew D Akanmori; Kojo A Koram; Lisa Ranford-Cartwright; Eleanor M Riley
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.